Corrigendum to “Next generation sequencing for whole genome analysis and surveillance of influenza A viruses” [J. Clin. Virol. 79 (2016) 44–50] (S1386653216300336), (10.1016/j.jcv.2016.03.005));Next generation sequencing for whole genome analysis and surveillance of influenza A viruses

Journal of Clinical Virology

Volumn 79, Issue , 2016, Pages 44-50

  McGinnis, Jana ^a   Laplante, Jennifer ^a   Shudt, Matthew ^a   George, Kirsten St ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

Antiviral resistance; Influenza surveillance; Molecular diagnosis; Molecular epidemiology; Next generation sequencing (NGS); Whole genome sequencing (WGS)

Indexed keywords

ANTIGENICITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; GENE MUTATION; GENOME ANALYSIS; INFLUENZA A VIRUS; NEXT GENERATION SEQUENCING; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PYROSEQUENCING; VIRAL TROPISM; VIRUS VIRULENCE; CLASSIFICATION; DNA SEQUENCE; EPIDEMIOLOGICAL MONITORING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MOLECULAR EPIDEMIOLOGY; NEW YORK; POLYMERASE CHAIN REACTION; PROCEDURES; VIROLOGY; VIRUS GENOME;

EPIDEMIOLOGICAL MONITORING; GENOME, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MOLECULAR EPIDEMIOLOGY; NEW YORK; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84962905988     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2017.06.004     Document Type: Erratum

References (23)

1. Poon L.L., Song T., Rosenfeld R., Lin X., Rogers M.B., Zhou B., Sebra R., Halpin R.A., Guan Y., Twaddle A., DePasse J.V., Stockwell T.B., Wentworth D.E., Holmes E.C., Greenbaum B., Peiris J.S., Cowling B.J., Ghedin E. Quantifying influenza virus diversity and transmission in humans. Nat. Genet. 2016, 48(2):195-200. 10.1038/ng.3479.
2. Zhou B., Donnelly M.E., Scholes D.T., St George K., Hatta M., Kawaoka Y., Wentworth D.E. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J. Virol. 2009, 83:10309-10313.
3. Zou S. A practical approach to genetic screening for influenza virus variants. J. Clin. Microbiol. 1997, 35:2623-2627.
4. Laplante J.M., Marshall S.A., Shudt M., Van T.T., Reisdorf E.S., Mingle L.A., Shult P.A., George K.St. Influenza antiviral resistance testing in New York and Wisconsin, 2006-2008: methodology and surveillance data. J. Clin. Microbiol. 2009, 47:1372-1378.
5. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids Symp. Ser. 1999, 41:95-98.
6. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
7. Smagala J.A., Dawson E.D., Mehlmann M., Townsend M.B., Kuchta R.D., Rowlen K.L. ConFind: a robust tool for conserved sequence identification. Bioinformatics 2005, 21:4420-4422.
8. Babady N.E., Laplante J.M., Tang Y.W., St George K. Detection of a transient R292K mutation in influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient. J. Clin. Microbiol. 2015, 53:1415-1418.
9. Chambers B.S., Parkhouse K., Ross T.M., Alby K., Hensley S.E. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep. 2015, 12:1-6.
10. Rehm H.L., Bale S.J., Bayrak-Toydemir P., Berg J.S., Brown K.K., Deignan J.L., Friez M.J., Funke B.H., Hegde M.R., Lyon E., Working Group of the American College of Medical G., Genomics Laboratory Quality Assurance C. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 2013, 15:733-747.
11. Ewing B., Green P. Base-calling of automated sequencer traces using phred II. Error probabilities. Genome Res. 1998, 8:186-194.
12. Schirmer M., Ijaz U.Z., D'Amore R., Hall N., Sloan W.T., Quince C. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucl. Acids Res. 2015, 43:e37.
13. Quinones-Mateu M.E., Avila S., Reyes-Teran G., Martinez M.A. Deep sequencing: becoming a critical tool in clinical virology. J. Clin. Virol. 2014, 61:9-19.
14. Orton R.J., Wright C.F., Morelli M.J., King D.J., Paton D.J., King D.P., Haydon D.T. Distinguishing low frequency mutations from RT-PCR and sequence errors in viral deep sequencing data. BMC Genomics 2015, 16:229.
15. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., Klimov A.I., Gubareva L.V. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir. Res. 2009, 81:16-24.
16. Schmieder R., Edwards R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One 2011, 6:e17288.
17. Marston D.A., McElhinney L.M., Ellis R.J., Horton D.L., Wise E.L., Leech S.L., David D., de Lamballerie X., Fooks A.R. Next generation sequencing of viral RNA genomes. BMC Genomics 2013, 14:444.
18. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., Xu X., Shaw M.W., Klimov A.I., Gubareva L.V. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 2010, 85:381-388.
19. Okomo-Adhiambo M., Demmler-Harrison G.J., Deyde V.M., Sheu T.G., Xu X., Klimov A.I., Gubareva L.V. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 2010, 54:1834-1841.
20. Tamura D., Nguyen H.T., Sleeman K., Levine M., Mishin V.P., Yang H., Guo Z., Okomo-Adhiambo M., Xu X., Stevens J., Gubareva L.V. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob. Agents Chemother. 2013, 57:6141-6146.
21. Mishin V.P., Sleeman K., Levine M., Carney P.J., Stevens J., Gubareva L.V. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses. Antivir. Res. 2014, 101:93-96.
22. Little K., Leang S.K., Butler J., Baas C., Harrower B., Mosse J., Barr I.G., Hurt A.C. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015, 20.
23. Neumann G., Kawaoka Y. Transmission of influenza A viruses. Virology 2015, (479-480):234-246.